688520 Sinocelltech Inc.
- 46.45
- +0.56+1.22%
Sinocelltech Inc. News
Shenzhou Cell (688520): Eight factor dosage turned a loss into a profit in 24Q1
The company achieved revenue of 1,887 billion yuan (+84.46%) in 2023, and achieved revenue of 3.29/4.79/571/508 million yuan in Q1 to Q4, respectively. The company's first production during the period
Shenzhou Cell (688520): Continued rapid release of recombinant eight factors helps the company to turn losses into profits
The company's performance in 2023 grew rapidly. For the first time in the first quarter of 2024, the company achieved revenue of 1,887 billion yuan, an increase of 84.46% over the previous year; net loss to mother was 396 million yuan, and the loss decreased year on year
Shenzhou Cell (688520): 1Q24 net profit reverses loss; focus on the progress of the Eight Factor overseas listing
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 613 million yuan, an increase of 86.3% over the previous year; net profit to mother was 74.197 million yuan, which turned a loss into a profit, mainly due to the eight factors of the restructuring of the company's core products (business
Shenzhou Cell (688520): Recombinant factor VIII continues to grow at a high level, and annual results are expected to continue to be released
Key investment points: Revenue for the first quarter of '24 was 613 million yuan, and the eight factor restructuring volume exceeded expectations of 613 million yuan in Q1, an increase of 86.3% over the previous year, and net profit to mother of 74.2 million yuan, an increase of 14 million yuan over the previous year
Express News | Shenzhou Cell: First quarter revenue of 613 million yuan, up 86.3% year on year
Shenzhou Cell (688520): R&D pipeline for rapid release of recombinant factor VIII continues to be rich
Core view On April 12, the company released its 2023 annual report, and the performance was in line with expectations. The company's main product restructuring factor VIII overcame increased competition and procurement adjustments throughout the year, and sales achieved rapid expansion, driving the company's significant performance
Huafu Securities released a research report on April 18 stating that it gave Shenzhou Cell (688520.SH) a purchase rating, and the target price was 62.84 yuan. The main reasons for the rating include: 1) the product matrix is beginning to take shape, and i
Huafu Securities released a research report on April 18 stating that it gave Shenzhou Cell (688520.SH) a purchase rating, and the target price was 62.84 yuan. The main reasons for the rating include: 1) the product matrix is beginning to take shape, and it has entered the national health insurance catalogue in 24 years and is expected to be rapidly scaled up; 2) the growth rate of R&D expenses is slowing down, and multiple competitive research pipelines are promoting clinical trials. (Mainichi Keizai Shimbun)
Shenzhou Cell (688520): Continued high growth on the revenue side, turning losses into inflection points
Key investment points: Revenue in the first quarter of '24 exceeded 600 million yuan. The eight factors of restructuring continued to rapidly release the company achieved revenue of 1,887 billion yuan for the full year of '23, an increase of 84.46% over the previous year, and a net loss of 396 million yuan to the mother, compared to the same period last year.
Sinocelltech Forecasts Return to Profit in Q1
Sinocelltech Group (SHA:688520) forecasts an attributable profit of between 60 million yuan and 80 million yuan in the first quarter, rebounding from a loss of 153 million yuan in the year-ago period.
Shenzhou Cell (688520.SH) made a pre-profit. The net profit for the first quarter is expected to be 60 million yuan to 80 million yuan, changing from loss to profit
Shenzhou Cell (688520.SH) announced that the company expects to become a parent company in the first quarter of 2024...
SDIC Securities released a research report on April 16 stating that it gave Shenzhou Cell (688520.SH) a purchase rating and the target price was 51.06 yuan. The main reasons for the rating include: 1) the company's gross margin increased slightly in 2023,
SDIC Securities released a research report on April 16 stating that it gave Shenzhou Cell (688520.SH) a purchase rating and the target price was 51.06 yuan. The main reasons for the rating include: 1) the company's gross margin increased slightly in 2023, and the cost ratio was optimized during the period; 2) the eight factor restructuring revenue grew rapidly, and the overseas layout continued to advance. (Mainichi Keizai Shimbun)
Shenzhou Cell (688520): The matrix of recombinant eight-factor rapid release commercial products is gradually being enriched
Event: The company released its 2023 annual report. Throughout 2023, the company achieved operating income of 1,887 billion yuan, a year-on-year increase of 84.46%; net profit attributable to mother - 396 million yuan, net profit not attributable to mother - 0.64
Shenzhou Cell-U (688520): Eight recombinant factors, high growth, focus on the company's commercialization progress
The 2023 results are in line with our expectations: revenue of 1,887 billion yuan, up 84.46% year on year; net loss to mother of 396 million yuan. Rapid revenue growth is eight factors in the restructuring of the company's core products
Shenzhou Cell (688520.SH) announced its 2023 annual results, with a net loss of 396 million yuan, and the loss narrowed
Shenzhou Cell (688520.SH) released its 2023 annual report. The company's revenue was 1,887 million yuan, up 84.46% year on year; net loss attributable to shareholders of listed companies was 396 million yuan, and losses narrowed; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 63.685 million yuan, which narrowed; basic loss per share was 0.89 yuan/share.
Sinocelltech's Unit Gets Nod to Trial Tumor Drug
Sinocelltech Group's (SHA:688520) unit, China Cell Engineering, will conduct clinical trials on the SCTB14 injection after receiving approval from China's National Medical Products Administration, acc
Shenzhou Cell (688520.SH): SCTB14 injection approved to conduct clinical trials for patients with advanced malignant solid tumors
Shenzhou Cell (688520.SH) issued an announcement. Recently, Shenzhou Cell Engineering Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials for patients with advanced malignant solid tumors, the product SCTB14 injection developed independently by the company.
Express News | Shenzhou Cell: Holding subsidiary product SCTB14 received a notice of approval for drug clinical trials
Shenzhou Cell (688520): High quality and low cost dual-drive biopharmaceutical industrialization platform
Key investment points: Focus on biopharmaceutical production process research and development, and recombinant coagulation factor VIII drives rapid revenue growth. The company was founded in 2002 by Dr. Xie Liangzhi. The management team has rich experience in large-scale production of antibodies and vaccines, and is committed to developing
Sinocelltech Group Limited's (SHSE:688520) Business Is Trailing The Industry But Its Shares Aren't
When close to half the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 7.1x, you may consider Sinocelltech Group Limited (SHSE:688520) as a stock to potentially
Shenzhou Cell (688520) depth: it has a biopharmaceutical+vaccine dual platform recombinant eight factor competitive advantage
The company is an innovative biopharmaceutical R&D company dedicated to developing biopharmaceuticals with differentiated competitive advantages. Focus on the development and industrialization of biopharmaceutical products in various fields of treatment and prevention, such as malignant tumors, self-immunity, infectious diseases, and genetic diseases, and independent research and development
Analysis
Price Target
No Data
